NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeoGenomics (NASDAQ: NEO) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference, to be held September 14–16, 2026, in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Management’s fireside chat is scheduled for Tuesday, Sept. 15, at 7:45 am ET. A live audio webcast of the session can be accessed here.
An archived replay of the session will be available on the Investor Relations section of the Company’s website at ir.neogenomics.com.
About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260901710219/en/
Investor Contact
InvestorRelations@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Source: NeoGenomics, Inc.